KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Inventory (2016 - 2026)

Biocryst Pharmaceuticals filings provide 14 years of Inventory readings, the most recent being $5.4 million for Q4 2025.

  • On a quarterly basis, Inventory fell 33.25% to $5.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.4 million, a 33.25% decrease, with the full-year FY2025 number at $5.4 million, down 33.25% from a year prior.
  • Inventory hit $5.4 million in Q4 2025 for Biocryst Pharmaceuticals, up from $5.2 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $29.8 million in Q1 2024 to a low of $4.4 million in Q2 2024.
  • Median Inventory over the past 5 years was $14.7 million (2021), compared with a mean of $16.2 million.
  • Biggest five-year swings in Inventory: surged 215.74% in 2022 and later plummeted 83.54% in 2024.
  • Biocryst Pharmaceuticals' Inventory stood at $15.8 million in 2021, then skyrocketed by 74.36% to $27.5 million in 2022, then increased by 4.18% to $28.7 million in 2023, then plummeted by 71.81% to $8.1 million in 2024, then plummeted by 33.25% to $5.4 million in 2025.
  • The last three reported values for Inventory were $5.4 million (Q4 2025), $5.2 million (Q3 2025), and $5.0 million (Q2 2025) per Business Quant data.